Injectable alcoholism drug developed

June 13, 2006

A U.S. biotech firm has reportedly developed a monthly injectable alcoholism treatment as a substitute for a daily pill.

The drug -- being marketed by Cephalon Inc., in Frazer, Pa. -- was developed by Alkermes Inc. of Cambridge, Mass., as an extended-release injection form of naltrexone.

The new drug, Vivitrol, works by blocking neurotransmitters believed to be associated with alcohol dependence, diminishing the craving for alcohol, the Philadelphia Inquirer reported Tuesday.

Vivitrol has been approved by the U.S. Food and Drug Administration for use by adults able to abstain from drinking alcohol in an outpatient setting, and who are not actively drinking when they begin treatment.

The monthly intramuscular shot will cost $695, with Alkermes and Cephalon sharing profits from Vivitrol sales, as well as developing future commercial uses, possibly to treat other addictions.

Researchers told the Inquirer Vivitrol will be administered only by healthcare personnel in offices, hospitals, and clinics, and the treatment will include counseling.

Copyright 2006 by United Press International

Explore further: Prisons fight opioids with $1,000 injection: Does it work?

Related Stories

Prisons fight opioids with $1,000 injection: Does it work?

November 14, 2016

U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the manufacturer has aggressively ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.